Myriad Genetics Outperforms Aspira Women's Health as Better Women's Diagnostics Stock

Industry
โดย Zacks Investment Research·Read original
Summary · why it matters

Myriad Genetics is the better-positioned stock in women's health diagnostics compared with Aspira Women's Health, according to a Zacks Investment Research analysis. Over the past three months, Aspira shares rose 2.5% while Myriad gained 20.4%, though Aspira rallied 81.8% over the past year versus Myriad's 38.5%. Aspira trades at a trailing 12-month enterprise value-to-sales multiple of 2.03, below its five-year median of 2.87, while Myriad's multiple sits at 0.70, below its five-year median of 2.07, both appearing attractively valued against the Zacks Medical sector average of 2.78. Myriad's diversified portfolio across oncology, women's health and mental health, broader commercial footprint and improving execution give it an edge over Aspira's narrower focus on gynecologic diagnostics and AI-powered test pipeline.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Myriad Genetics Inc
MYGN
▲ PositiveCapitalrelevance

Zacks analysis highlights Myriad's diversified portfolio, broader commercial footprint, and improving execution as advantages, positioning it as the better women's diagnostics stock.

Off-coverage companies 1

Aspira Women's HealthPrivate▼ Negative
Competitionrelevance

Zacks analysis states Myriad is better-positioned than Aspira, citing Aspira's narrower focus and weaker performance comparison.

© 2026 MarketDXNews